×
About 61,558 results

ALLMedicine™ Squamous Cell Carcinoma Center

Research & Reviews  22,888 results

Visfatin Polymorphisms, Lifestyle Risk Factors and Risk of Oral Squamous Cell Carcinoma...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9108409
International Journal of Medical Sciences; Chen KJ, Hsieh MH et. al.

May 19th, 2022 - Oral cancer is the eighth greatest generally diagnosed cancer amongst males worldwide and the fourth most generally malignancy amongst Taiwanese males. The pro-inflammatory adipocytokine visfatin promotes tumor growth. Elevated plasma visfatin lev...

CT findings of basaloid squamous cell carcinoma of the lung in 12 patients: A distinct ...
https://doi.org/10.1097/MD.0000000000029197 10.1371/journal.pone.0223298 10.7717/peerj.6724
Medicine Kim CH, Cha YK et. al.

May 19th, 2022 - Basaloid squamous cell carcinoma (SCC) is very rare subtype of SCC of the lung and it is important to distinguish basaloid to other subtypes of SCCs, since the prognosis of basaloid subtype is considered poorer than that of other non-basaloid subt...

Survival and clinicopathological characteristics of cT4b oral squamous cell carcinoma b...
https://doi.org/10.1097/MD.0000000000029285
Medicine Lin NC, Hsu JT et. al.

May 19th, 2022 - Primary surgical treatment for oral squamous cell carcinoma (OSCC) is reserved for T1 to T4a tumors, but not for T4b tumors, according to the present National Comprehensive Cancer Network clinical practice guidelines. In this retrospective study, ...

Prognostic impact of preoperative Geriatric Nutritional Risk Index in oral squamous cel...
https://doi.org/10.1111/odi.14255
Oral Diseases; Ito Y, Abe A et. al.

May 19th, 2022 - To investigate the prognostic impact of preoperative Geriatric Nutritional Risk Index (GNRI) values in older adults undergoing radical surgery for oral squamous cell carcinoma (OSCC). This retrospective study included 61 patients ≥ 65 years old wi...

see more →

Guidelines  36 results

Clinical features, molecular characteristics and surgical management of primary penile ...
https://doi.org/10.1097/CMR.0000000000000788
Melanoma Research; Cakir OO, Pozzi E et. al.

Nov 30th, 2021 - Penile mucosal melanoma is an aggressive and rare genital malignancy. The aim of the present study was to review the management and outcomes of a homogenous cohort of patients with histologically confirmed penile mucosal melanoma, at a single spec...

Poor tumor differentiation is an independent adverse prognostic variable in patients wi...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8495291
Cancer Medicine; Lee LY, Lin CY et. al.

Sep 18th, 2021 - We sought to compare the prognostic impact of tumor differentiation with respect to adverse risk factors (RFs) identified by the National Comprehensive Cancer Network (NCCN) guidelines--including extranodal extension (ENE), positive/close margins,...

ACR Appropriateness Criteria® Staging and Follow-up of Vulvar Cancer.
https://doi.org/10.1016/j.jacr.2021.02.016
Journal of the American College of Radiology : JACR; , Lakhman Y et. al.

May 8th, 2021 - Vulvar cancer is an uncommon gynecologic tumor and one of several human papillomavirus-associated malignancies. Squamous cell carcinoma is the most prevalent histologic subtype of vulvar cancer, accounting for the majority of cases. Imaging plays ...

Summary of the updated 2020 guidelines for cutaneous squamous cell carcinoma.
https://doi.org/10.1111/ced.14587
Clinical and Experimental Dermatology; Woo WA, Suarez M-Falero B et. al.

Mar 18th, 2021 - Summary of the updated 2020 guidelines for cutaneous squamous cell carcinoma.|2021|Woo WA,Suarez M-Falero B,Keohane SG,|pathology,therapy,pathology,therapy,

Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ES...
https://doi.org/10.1016/j.annonc.2020.07.011
Annals of Oncology : Official Journal of the European Soc... Machiels JP, René Leemans C et. al.

Nov 27th, 2020 - Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2020|Machiels JP,René Leemans C,Golusinski W,Grau C,Licitra L,|diagnosis,epidemiol...

see more →

Drugs  44 results see all →

Clinicaltrials.gov  641 results

HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers
https://clinicaltrials.gov/ct2/show/NCT04432597

May 13th, 2022 - Background Metastatic HPV associated malignancies (cervical, anal, oropharyngeal cancers, etc.) are often incurable and poorly palliated by standard therapies. HPV-positive (p16+) oropharyngeal cancers are the most common HPV-associated malignancy...

Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Car...
https://clinicaltrials.gov/ct2/show/NCT04428151

May 13th, 2022 - This study is designed to assess the safety and efficacy of lenvatinib in combination with pembrolizumab versus standard of care (SOC) chemotherapy, and to also assess the safety and efficacy of lenvatinib monotherapy in participants with recurren...

Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer
https://clinicaltrials.gov/ct2/show/NCT04847466

May 13th, 2022 - Background: Natural killer (NK) cells are an important component of an anti-tumor immune response. PD-L1 CAR-NK (PD-L1 t-haNKs) is an off the shelf, irradiated human, allogeneic, NK cell line that is frozen, shipped, thawed and then infused. PD-L1...

Study of INCA 0186 in Subjects With Advanced Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT04989387

May 13th, 2022 - This is an open-label, nonrandomized, multicenter, dose escalation, and dose expansion first-in human (FIH) Phase 1 study to determine the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of INCA00186 when given alone or in com...

The Oral Microbiome in OSCC
https://clinicaltrials.gov/ct2/show/NCT04925700

May 13th, 2022 - Previous work by a number of scientific teams has revealed that the types of bacteria that colonize the mouth differ between health and pre-cancerous or cancerous oral lesions. The purpose of this study is to investigate the extent of these change...

see more →

News  996 results

Studies Address Ibrutinib Bleeding Risk in Patients With CLL Receiving Mohs Surgery
https://www.medscape.com/viewarticle/974234

May 18th, 2022 - Patients receiving treatment with ibrutinib for chronic lymphocytic leukemia (CLL) show significant increases in the risk for bleeding when undergoing Mohs micrographic surgery for skin cancer, indicating the need for temporary treatment interrupt...

Olson Grade, Need for More Treatment Are Markers of Increased Skin Cancer Risk in Actinic Keratoses
https://www.medscape.com/viewarticle/973526

May 6th, 2022 - NEW YORK (Reuters Health) - In patients with multiple actinic keratoses (AKs), Olson grade III and the need for more treatment were identified as markers for increased risk of cutaneous squamous cell carcinoma (cSCC) in a secondary analysis of a r...

Pembrolizumab With or Without Chemo Has Increased Efficacy With Increasing PD-L1 Expression in HNSCC
https://www.onclive.com/view/pembrolizumab-with-or-without-chemo-has-increased-efficacy-with-increasing-pd-l1-expression-in-hnscc

May 4th, 2022 - Pembrolizumab (Keytruda) with or without chemotherapy resulted in a numerically longer overall survival (OS) benefit vs cetuximab (Erbitux) plus chemotherapy in patients with head and neck squamous cell carcinoma (HNSCC) and a PD-L1 combined posit...

SOT101 Plus Pembrolizumab Elicits Encouraging Efficacy in Advanced Solid Tumors
https://www.onclive.com/view/sot101-plus-pembrolizumab-elicits-encouraging-efficacy-in-advanced-solid-tumors

May 2nd, 2022 - The addition of SOT101, an interleukin (IL)-2/IL-15 Rβγ superagonist, to Pembrolizumab (Keytruda) generated a clinical benefit and encouraging safety data in patients with advanced solid tumors, according to data presented at the 2022 AACR Annual ...

Extra COVID Jab for Cancer Patients; VA to Cover More Cancers; Cancer's Origin Story
https://www.medpagetoday.com/hematologyoncology/othercancers/98467

Apr 29th, 2022 - The National Comprehensive Cancer Network endorsed a second COVID mRNA booster for immunocompromised individuals, bringing the total to five jabs, as three is considered standard for someone who is immunocompromised. In a first-quarter earnings st...

see more →

Patient Education  18 results see all →